{
    "id": 4927,
    "name": "Klatskin's tumor",
    "source": "DOID",
    "definition": "An intrahepatic cholangiocarcinoma arising near or at the confluence of the right and left hepatic ducts. [url:https\\://meshb.nlm.nih.gov/record/ui?ui=D018285]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "5246"
    ],
    "termId": "DOID:4927",
    "evidence": [
        {
            "id": 12378,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a pilot clinical trial, Rapamune (sirolimus) demonstrated modest clinical activity in patients with PIK3CA-mutant gastric cancer (n=3) or hilar cholangiocarcinoma (n=1; harboring PIK3CA E545K), with a 0% response rate, median progression-free survival of 1.9 months, and median overall survival of 3.6 months (PMID: 28685070).",
            "molecularProfile": {
                "id": 2421,
                "profileName": "PIK3CA E545K"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4927,
                "name": "Klatskin's tumor",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 10344,
                    "pubMedId": 28685070,
                    "title": "Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28685070"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        
    ]
}